The notion that CP treatments potentially modulate AD-related immune responses, together with the fact that inflammasomes and AD are strictly related, led us to focus on NLRP3 inflammasome activation and quantify the relevant mediators/byproducts. This evidence concerns the gene NLRP3 and Alzheimer disease.